Airmid Healthgroup is proud to announce that our laboratory has achieved ISO 17025 accreditation for the quantification of influenza A nucleoprotein, further strengthening our capabilities in high-quality aerobiology and virology testing of airborne viruses.
Airmid Healthgroup provides ISO/IEC 17025 accredited testing services for a range of airborne biological agents, including the Influenza A virus, house dust mite allergen (Der p 1), and cat allergen (Fel d 1). This extension of our scope of accreditation builds on our achievement in 2011, when our laboratory became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 and Fel d 1 analysis.
ISO/IEC 17025 is the globally recognised standard defining the technical competence requirements for testing and calibration laboratories.
As an ISO 17025 accredited testing laboratory, Airmid Healthgroup operates under a comprehensive quality system that governs both management practices and technical performance. This accreditation assures customers that our laboratory delivers accurate, reliable, and scientifically robust data.
ISO/IEC 17025 accreditation for Influenza A testing has been achieved by Airmid Lab following formal assessment by the Irish National Accreditation Board (INAB). This ISO/IEC 17025 accreditation covers the quantification of Influenza A nucleoprotein and strengthens Airmid Lab’s capability to support virus research and validated analytical testing. INAB is the sole accreditation body in Ireland, and reports issued by INAB-accredited laboratories are internationally recognised through Multilateral Agreements (MLAs) with global accreditation organisations, including the International Laboratory Accreditation Cooperation (ILAC).
With the motto “tested once, accepted everywhere”, The ILAC Mutual Recognition Arrangement (MRA), supports international trade. The ILAC-MRA mark in combination with the INAB symbol on a report provides confidence in the accuracy of the results, as it signifies that the testing was performed by a facility that has been assessed as being competent to carry out that specific activity. This combined mark will be used in all airmid healthgroup reports that contain results reported under their defined scope of activity for ISO/IEC 17025:2005.
Influenza is a virus of critical interest in the global drive to reduce ill health caused by indoor air pollutants because it is globally distributed and highly contagious. The flu illness can range in severity from mild to serious. For centuries, influenza has caused both epidemics and pandemics. Despite the modern-day availability of vaccines to prevent influenza infection, annual epidemics continue to be a worldwide issue.
“This achievement represents an important milestone for the company as it continues to lead the way in the research, development and testing of products and services that can contribute to health and wellness in the indoor environment” said the CEO of airmid healthgroup.
airmid healthgroup carries out third party testing and research for global manufacturers of consumer products designed to create a healthier indoor environment such as air cleaners, filters, textiles, surface coatings, hand dryers and cleaning products. Testing to determine the ability of these products to block or remove indoor air contaminants is carried out in airmid healthgroup’s state of the art environmental test chambers with rapid analysis of samples in adjacent allergen, microbiology and virology laboratories.
